Zacks: Tocagen Inc (TOCA) Receives Average Recommendation of “Buy” from Brokerages
Tocagen Inc (NASDAQ:TOCA) has been given a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Analysts have set a 1 year consensus price target of $23.67 for the company and are anticipating that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also given Tocagen an industry rank of 179 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th.
Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. equities research analysts expect that Tocagen will post -2.66 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. New York State Common Retirement Fund purchased a new position in Tocagen in the 2nd quarter valued at $108,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Tocagen during the 2nd quarter worth $165,000. BBR Partners LLC purchased a new stake in shares of Tocagen during the 3rd quarter worth $181,000. California State Teachers Retirement System purchased a new stake in shares of Tocagen during the 2nd quarter worth $179,000. Finally, Teachers Advisors LLC purchased a new stake in shares of Tocagen during the 2nd quarter worth $181,000. Hedge funds and other institutional investors own 36.22% of the company’s stock.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.